HBOT research suggests that it may be a valuable adjunctive therapy for Cerebral Palsy, Multiple Sclerosis, Lyme Disease and other neurological conditions. HBOT has been found to improve the cerebral metabolic rate, reduce cerebral edema, improve cerebral blood flow and reduce cerebral spinal fluid lactic acid levels.
Based on current thinking about the biology of Cerebral Palsy and Multiple Sclerosis, HBOT may be a valuable adjunct to conventional therapy.
In the case of Lyme Disease, it has been demonstrated the bacteria responsible for Lyme Disease, Borrelia burgdoferi, can survive in oxygen at sea level, but cannot live in an environment of high pressure oxygen. It is also known that this particular bacteria can become sequestered in cells and the cells may protect it from antibiotics, resulting in chronic Lyme Disease and persistent neurologic symptoms. In a study of 90 patients diagnosed with Lyme Disease unresponsive to antibiotics, the use of HBOT resulted in a significant decrease or elimination of symptoms and improved quality of life for 85% of patients.